Evolving Role of Catheter Ablation for Atrial Fibrillation: Early and Effective Rhythm Control
Standard
Evolving Role of Catheter Ablation for Atrial Fibrillation: Early and Effective Rhythm Control. / Chen, Shaojie; Yin, Yuehui; Ling, Zhiyu; Meyer, Christian; Pürerfellner, Helmut; Martinek, Martin; Kiuchi, Márcio Galindo; Futyma, Piotr; Zhu, Lin; Schratter, Alexandra; Wang, Jiazhi; Acou, Willem-Jan; Sommer, Philipp; Ouyang, Feifan; Liu, Shaowen; Chun, Julian K R; Schmidt, Boris.
in: J CLIN MED, Jahrgang 11, Nr. 22, 6871, 21.11.2022.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Evolving Role of Catheter Ablation for Atrial Fibrillation: Early and Effective Rhythm Control
AU - Chen, Shaojie
AU - Yin, Yuehui
AU - Ling, Zhiyu
AU - Meyer, Christian
AU - Pürerfellner, Helmut
AU - Martinek, Martin
AU - Kiuchi, Márcio Galindo
AU - Futyma, Piotr
AU - Zhu, Lin
AU - Schratter, Alexandra
AU - Wang, Jiazhi
AU - Acou, Willem-Jan
AU - Sommer, Philipp
AU - Ouyang, Feifan
AU - Liu, Shaowen
AU - Chun, Julian K R
AU - Schmidt, Boris
PY - 2022/11/21
Y1 - 2022/11/21
N2 - Catheter Ablation (CA) is an effective therapeutic option in treating atrial fibrillation (AF). Importantly, recent data show that CA as a rhythm control strategy not only significantly reduces AF burden, but also substantially improves clinical hard endpoints. Since AF is a progressive disease, the time of Diagnosis-to-Intervention appears crucial. Recent evidence shows that earlier rhythm control is associated with a lower risk of adverse cardiovascular outcomes in patients with early AF. Particularly, CA as an initial first line rhythm control strategy is associated with significant reduction of arrhythmia recurrence and rehospitalization in patients with paroxysmal AF. CA is shown to significantly lower the risk of progression from paroxysmal AF to persistent AF. When treating persistent AF, the overall clinical success after ablation remains unsatisfactory, however the ablation outcome in patients with "early" persistent AF appears better than those with "late" persistent AF. "Adjunctive" ablation on top of pulmonary vein isolation (PVI), e.g., ablation of atrial low voltage area, left atrial posterior wall, vein of Marshall, left atrial appendage, etc., may further reduce arrhythmia recurrence in selected patient group. New ablation concepts or new ablation technologies have been developing to optimize therapeutic effects or safety profile and may ultimately improve the clinical outcome.
AB - Catheter Ablation (CA) is an effective therapeutic option in treating atrial fibrillation (AF). Importantly, recent data show that CA as a rhythm control strategy not only significantly reduces AF burden, but also substantially improves clinical hard endpoints. Since AF is a progressive disease, the time of Diagnosis-to-Intervention appears crucial. Recent evidence shows that earlier rhythm control is associated with a lower risk of adverse cardiovascular outcomes in patients with early AF. Particularly, CA as an initial first line rhythm control strategy is associated with significant reduction of arrhythmia recurrence and rehospitalization in patients with paroxysmal AF. CA is shown to significantly lower the risk of progression from paroxysmal AF to persistent AF. When treating persistent AF, the overall clinical success after ablation remains unsatisfactory, however the ablation outcome in patients with "early" persistent AF appears better than those with "late" persistent AF. "Adjunctive" ablation on top of pulmonary vein isolation (PVI), e.g., ablation of atrial low voltage area, left atrial posterior wall, vein of Marshall, left atrial appendage, etc., may further reduce arrhythmia recurrence in selected patient group. New ablation concepts or new ablation technologies have been developing to optimize therapeutic effects or safety profile and may ultimately improve the clinical outcome.
U2 - 10.3390/jcm11226871
DO - 10.3390/jcm11226871
M3 - SCORING: Review article
C2 - 36431348
VL - 11
JO - J CLIN MED
JF - J CLIN MED
SN - 2077-0383
IS - 22
M1 - 6871
ER -